Insight

Oct 31, 2024, 06:01

Nico Gagelmann: Bs Abs as bridging to BCMA CAR-T cell therapy for R/R multiple myeloma

Nico Gagelmann, Co- Chair of the The EBMT Trainee Committee, shared on X:

“Finally out!

Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma.”

Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma

Authors: David Fandrei, Sabine Seiffert, Michael Rade, Susanne Rieprecht, Nico Gagelmann, Patrick Born, Thomas Wiemers, Heike Weidner, Markus Kreuz, Tamara Schassberger, Jannik Kossmann, Marlene Mangold, Daniel Furst, Luise Fischer, Ronny Baber, Simone Heyn, Song Yau Wang, Enrica Bach, Sandra Hoffmann, Klaus H. Metzeler, Marco Herlling, Madlen Jentzsch, Georg-Nikolaus Franke, Ulrike Kohl, Maik Friedrich, Andreas Boldt, Kristin Reiche, Uwe Platzbecker, Vladan Vucinic, Maximilian Merz.

Nico Gagelmann

Andreas Boldt Bispecific antibodies cancer Daniel Furst David Fandrei Enrica Bach Georg-Nikolaus Franke Heike Weidner Jannik Kossmann Klaus H Metzeler Kristin Reiche Luise Fischer Madlen Jentzsch Maik Friedrich Marco Herlling Markus Kreuz Marlene Mangold Maximilian Merz Michael Rade multiple myeloma Nico Gagelmann OncoDaily Oncology Patrick Born Ronny Baber Sabine Seiffert Sandra Hoffmann Simone Heyn Song Yau Wang Susanne Rieprecht Tamara Schassberger Thomas Wiemers Ulrike Köhl Uwe Platzbecker Vladan Vucinic

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage